Ldl-C Lowering Efficacy of Evolocumab (Amg 145) Could Reduce Apheresis in Patients At High Risk for Cardiovascular Events in Germany
Value Health
.
2014 Nov;17(7):A504-5.
doi: 10.1016/j.jval.2014.08.1528.
Epub 2014 Oct 26.
Authors
G Villa
1
,
T Schmid
2
,
M Lothgren
1
,
G Michailov
2
Affiliations
1
Amgen (Europe) GmbH, Zug, Switzerland.
2
Amgen GmbH, München, Germany.
PMID:
27201533
DOI:
10.1016/j.jval.2014.08.1528
No abstract available